Adam Feuerstein, STAT

Adam Feuerstein


Boston, MA, United States

Contact Adam

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Unknown
  • STAT
  • CNBC
  • Business Insider
  • The Boston Globe
  • Fox News
  • TheStreet

Past articles by Adam:

Amylyx’s ALS drug launch starts strong. That could be trouble for the FDA

Behind the stellar launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug make it more complicated to pull it from the market if we find out next year that it doesn’t work? → Read More

Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion

Pfizer said it is acquiring Seagen, a maker of targeted cancer drugs, for $43 billion. → Read More

FDA approves first treatment for Rett syndrome, a genetic neurological disease

The FDA has approved the first treatment for Rett syndrome, a genetic disease mostly affecting girls that causes severe neurologic impairments. → Read More

SVB, biotech’s bank of choice, just failed. It could have ripple effects

Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech companies, failed on Friday. Now biotech startups are left wondering: Who’s going to finance the industry? → Read More

Listen: The next CRISPR fight, cheaper insulin, & an FDA shuffle

Who invented CRISPR 2.0? What happens when a drug company actually lowers prices? And is Novavax going to survive? STAT's podcast covers all that and more. → Read More

FDA approves Reata's treatment for rare neurological disease

The Food and Drug Administration approved the first drug to treat Friedreich’s Ataxia, a rare, neurological disease. → Read More

New head of FDA’s neuroscience office takes over at crucial time

The new head of the FDA's Office of Neuroscience is stepping into an increasingly powerful position at the agency. → Read More

FDA's Billy Dunn to leave the agency

Billy Dunn, who presided over the polarizing approval of the Alzheimer’s disease treatment Aduhelm, is leaving the FDA after more than 15 years at the agency. → Read More

For Cytokinetics, an FDA rejection of its heart drug would help, not hinder

For investors, an FDA rejection of Cytokinetics' heart drug would, perhaps unexpectedly, be a welcome relief. → Read More

Listen: Vertex vs. insurers, Moderna's future, & biotech's long winter

What makes a drug quintuple in cost? How do you follow inventing a Covid-19 vaccine? And what did we learn from biotech's unicorn era? Find out on the latest episode of "The Readout LOUD." → Read More

Once high-flying Rubius to shut down. Its flameout is a lesson for biotech

The official end of Rubius Therapeutics marks one of biotech’s highest-profile flameouts. → Read More

‘Practice changing’: Antibody treatment benefits leukemia patients receiving bone marrow transplant

An experimental antibody that delivers lethal radiation directly to the bone marrow improved the outcomes of stem cell transplants for older patients with relapsed leukemia — and may change the way transplant medicine is practiced. → Read More

FDA approves first treatment for leading cause of blindness in older people

The FDA approved the first treatment for geographic atrophy, a progressive eye disease and a leading cause of blindness in older people. → Read More

Christi Shaw, leader of Gilead’s cancer cell therapy unit, to depart

Christi Shaw, the CEO of Gilead’s Kite Pharmaceuticals cell therapy unit, is leaving the company, Gilead said Friday in a statement. → Read More

Reata's 'toss up' drug approval decision is in the unpredictable hands of FDA's Billy Dunn

Will Dunn apply the doctrine of “regulatory flexibility” to a medicine with less-than-convincing clinical data? → Read More

Novartis CEO Vas Narasimhan talks PhRMA, gene therapy, and much more

Vas Narasimhan has been CEO of Novartis since 2018. He talked with STAT about the industry's struggles in Washington, the future of Novartis, and whether the biotech sector is still a little overvalued. → Read More

Listen: Vas Narasimhan on the future of pharma, plus Moderna’s vaccine promise & a biotech presidential bid

Is the pharmaceutical lobby on the ropes? What does it mean when a vaccine is "free"? And does biotech prepare you for the presidency? All that and more on the new episode of "The Readout LOUD." → Read More

Biogen, having ‘lost its way,’ looks to drug launches for Alzheimer’s and depression for return to growth

“We have two major products to launch ... that’s not an opportunity you have very often," said Biogen CEO Chris Viehbacher. → Read More

A CAR-T from Bristol Myers benefits myeloma patients at earlier stage of care

The CAR-T cancer therapy called Abecma reduced the risk of multiple myeloma relapse by half compared to standard treatment. → Read More

The return of bird flu and the effects of pandemic fatigue

Just how alarming is bird flu? And did we learn enough from Covid-19 to be sensible about it? All that and more on the new episode of "The Readout LOUD" podcast. → Read More